ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.190,00
0,14%
S&P 500
5.477,90
0,16%
Dow Jones
39.127,80
0,00%
Euro vs US Dollar
1,07009
0,20%
Bitcoin
61.156,29
0,56%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Landos Biopharma Inc (LABP)

  7. Landos Biopharma Inc (LABP) News

LABP

Landos Biopharma (LABP)

Landos Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LABP
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202412h04Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202422h52Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:LABPLandos Biopharma Inc
23/05/202422h49Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h48Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h47Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h46Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
23/05/202422h05PR Newswire (US)AbbVie Completes Acquisition of Landos BiopharmaNASDAQ:LABPLandos Biopharma Inc
23/05/202418h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
09/05/202414h32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LABPLandos Biopharma Inc
25/03/202413h31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNASDAQ:LABPLandos Biopharma Inc
25/03/202413h30GlobeNewswire Inc.AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNASDAQ:LABPLandos Biopharma Inc
04/03/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
04/03/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LABPLandos Biopharma Inc
04/01/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
21/11/202314h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
09/11/202314h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LABPLandos Biopharma Inc
09/11/202314h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
21/09/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
14/09/202314h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
09/08/202314h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LABPLandos Biopharma Inc
09/08/202314h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
01/06/202322h20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:LABPLandos Biopharma Inc
25/05/202322h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LABPLandos Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:LABP

Kürzlich von Ihnen besucht

EU
TBIRD
Thunderbird Resorts
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten